Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2,595 | $2,694 | $3,387 | $5,121 |
| - Cash | $293 | $132 | $399 | $1,479 |
| + Debt | $549 | $171 | $448 | $418 |
| Enterprise Value | $2,850 | $2,733 | $3,435 | $4,059 |
| Revenue | $519 | $33 | $561 | $449 |
| % Growth | 1,466.6% | -94.1% | 25.1% | – |
| Gross Profit | $321 | -$35 | $307 | $235 |
| % Margin | 61.8% | -105.3% | 54.7% | 52.3% |
| EBITDA | $209 | $188 | -$118 | -$52 |
| % Margin | 40.3% | 567.6% | -21% | -11.5% |
| Net Income | -$25 | $3,137 | -$175 | -$2 |
| % Margin | -4.9% | 9,473% | -31.2% | -0.4% |
| EPS Diluted | -0.012 | 1.44 | -0.083 | -0.001 |
| % Growth | -100.8% | 1,841.2% | -9,088.9% | – |
| Operating Cash Flow | $233 | -$4 | $80 | -$96 |
| Capital Expenditures | -$32 | -$14 | -$134 | -$76 |
| Free Cash Flow | $200 | -$18 | -$54 | -$172 |